(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3(Date:10/2/2008)...IS, October 2 /- Pharmaleads has obta... authorization to perform a single,ascending dose ...l,treatment of neuropathic pain., Neuropathic pai...ated,prevalence in the world,s population of up to...ny causes such as shingles, herpes, diabetes,anti...
(Date:10/2/2008)...CKHOLM, October 2 /- Athera Biotechno... today that they have entered into a,collaboration...or the,prevention or treatment of cardiovascular i...the recent publication of work by Athera,scientifi...the Karolinska,Institutet. The research links natu...
(Date:10/2/2008)...ata Indicate Dual Modes of Action and Synergy with...ll/ -- Access Pharmaceuticals, Inc.,(OTC Bulletin ...ical,studies on Angiolix showing that by blocking ...effect as well as a direct anti-proliferative effe...human breast cancer (MX-1),Angiolix had a signifi...
(Date:10/1/2008)...pport the therapeutic potential of Amylin,s integr...esity pharmacotherapy, SAN DIEGO, Oct. 1 /PRNewsw...sdaq: AMLN ) today announced that new data for it... the 2008 Annual Scientific Meeting of The,Obesity...ty,s annual,meeting is one of the largest and most...
Breaking Medicine Technology:Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences 1677 1Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences 1677 2Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences 1677 3New Scan Sees Tumors Deep Inside Body 15749 1New Scan Sees Tumors Deep Inside Body 15749 2MedCath Announces Acquisition of Ownership in Arizona Cath Lab 15744 1MedCath Announces Acquisition of Ownership in Arizona Cath Lab 15744 2STAAR Surgical Plans Major Presence at ASCRS 15740 1STAAR Surgical Plans Major Presence at ASCRS 15740 2STAAR Surgical Plans Major Presence at ASCRS 15740 3...RE)--Apr 10, 2007 - Inotek,Pharmaceuticals Corpora...l Stroke of preclinical animal data showing that t... (PARP) inhibitor,has a large protective effect on...troke. PARP is a nuclear enzyme that directs the,r...tment of DNA,repair enzymes and has potential appl...
...RNewswire-FirstCall/ -- ImClone,Systems Incorporat...d that a Phase III study of ERBITUX(R) (Cetuximab)...h locally advanced,unresectable or metastatic panc... improving overall survival. , Conducted by the So...work sponsored by the National Cancer Institute, t...
Other Medicine Technology:Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 2Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 3Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 2Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 3Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 4Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 5Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 6Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 8Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 9...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
Medicine Products: